(Q34245740)

31 July 2017

MDV3100 for the treatment of prostate cancer (English)

1 reference

31 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1 reference

Deborah Mukherji

1

1 reference

31 July 2017

Carmel J Pezaro

series ordinal

2

1 reference

31 July 2017

Johann S De-Bono

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

10 January 2012

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

21

1 reference

31 July 2017

227-233

1 reference

31 July 2017

2

1 reference

31 July 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

The androgen axis in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

The evolving role of estrogen therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Management of advanced prostate cancer after first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

New therapies for castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

CYP17 inhibition as a hormonal strategy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651125

10.1517/13543784.2012.651125

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference